Tris Pharma, a specialty pharmaceutical company, agreed to acquire Park Therapeutics, a development focused biotechnology company. Financial terms were not disclosed. "I have been pleasantly surprised to see the depth and breadth of data underscoring the superiority of treatment that this drug promises. We are fortunate to have this opportunity to acquire a late-stage asset and look forward to working with the FDA on its approval journey," Ketan Mehta, Tris Pharma Founder and CEO.